Johns Hopkins University · Biomedical EngineeringTheranostics for Blood Cancer Lab
Sridhar Nimmagadda · Baltimore, Maryland
Research Focus
Dr. Sridhar Nimmagadda's lab focuses on improving the diagnosis and treatment of blood cancers like multiple myeloma and lung cancer through innovative theranostic approaches. They aim to create advanced imaging agents and targeted therapies that can effectively measure and combat cancer while reducing the need for invasive procedures. By developing new, easy-to-use radiopharmaceuticals, the lab seeks to enhance the precision of immunotherapy treatments and improve patient outcomes.
theranosticsmultiple myelomaPET imagingPD-L1cancer therapyradiopharmaceuticalsalpha-emitter therapynon-invasive biomarkersimmune checkpoint therapybiomarker panels
Research Aims
5AIM 01Develop a peptide-based theranostic agent targeting CD38 for multiple myeloma.
AIM 02Create a Gallium-68 radiopharmaceutical to measure PD-L1 levels.
AIM 03Facilitate non-invasive imaging to guide cancer immunotherapy.
AIM 04Enhance existing cancer therapies to overcome drug resistance.
AIM 05Translate research findings into clinical applications for patient benefit.
Skills the Lab Values
peptide synthesisradiolabeling techniquesPET imagingtheranostic developmentcell cultureanimal modelsbiochemical assaysimmunohistochemistrypharmacokineticsclinical trial design
Output against the department
Publications203bottom 47% of dept.313th of 595
this lab
most publishedleast published
Citations6.7ktop 49% of dept.294th of 595
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.